---
title: "Linzess (linaclotide), all indications: Specific populations questions"
description: "Specific populations questions on Linzess (linaclotide) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Pregnancy and breastfeeding. Questions: Can Linzess be used during pregnancy? Can Linzess be used while breastfeeding? Does Linzess need a dose adjustment for kidney or liver impairment? What happens after a Linzess overdose? 4 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/linzess/specific-populations"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Linzess (linaclotide), all indications: Specific populations questions

Manufacturer: AbbVie, Inc.; Ironwood Pharmaceuticals, Inc.  
Prescribing information: [Linzess](https://www.rxabbvie.com/pdf/linzess_pi.pdf)  
Indication pages: [Irritable bowel syndrome with constipation](https://www.evicenter.com/medical-information/linzess--irritable-bowel-syndrome-with-constipation)

## Pregnancy and breastfeeding

<a id="linzess-pregnancy"></a>

### Can Linzess be used during pregnancy?

> “Linaclotide and its active metabolite are negligibly absorbed systemically following oral 
> administration [see Clinical Pharmacology (12.3)], and maternal use is not expected to result in 
> fetal exposure to the drug. The available data on LINZESS use in pregnant women are not 
> sufficient to inform any drug-associated risk for major birth defects and miscarriage. In animal 
> developmental studies, no effects on embryo-fetal development were observed with oral 
> administration of linaclotide in rats and rabbits during organogenesis at doses much higher 
> than the maximum recommended human dosage. Severe maternal toxicity associated with 
> effects on fetal morphology were observed in mice (see Data).”

Source: [LINZESS: Prescribing information, page 9, captured 2026-11-14](https://www.rxabbvie.com/pdf/linzess_pi.pdf#page=9)

<a id="linzess-breastfeeding"></a>

### Can Linzess be used while breastfeeding?

> “Linaclotide and its active metabolite were not detected in the milk of lactating women (see 
> Data). In adults, concentrations of linaclotide and its active metabolite were below the limit of 
> quantitation in plasma following multiple doses of LINZESS [see Clinical Pharmacology (12.3)]. 
> Maternal use of LINZESS is not expected to result in exposure to linaclotide or its active 
> metabolite in breastfed infants. There is no information on the effects of linaclotide or its active 
> metabolite on milk production. The developmental and health benefits of breastfeeding should 
> be considered along with the mother’s clinical need for LINZESS and any potential adverse 
> effects on the breastfed infant from LINZESS or from the underlying maternal condition.”

Source: [LINZESS: Prescribing information, page 10, captured 2026-11-14](https://www.rxabbvie.com/pdf/linzess_pi.pdf#page=10)

> “Following oral administration of 72 mcg, 145 mcg, or 290 mcg of LINZESS once daily for 3 
> days to breastfeeding mothers taking linaclotide therapeutically, the concentrations of 
> linaclotide and its metabolite were below the limits of quantitation (<0.25 ng/mL and <1 ng/mL, 
> respectively) in all breast milk samples collected over 24 hours.”

Source: [LINZESS: Prescribing information, page 10, captured 2026-11-14](https://www.rxabbvie.com/pdf/linzess_pi.pdf#page=10)

## Specific populations

<a id="linzess-kidney-liver"></a>

### Does Linzess need a dose adjustment for kidney or liver impairment?

> “Dosing adjustments for patients with renal or hepatic impairment are not required”

Source: [LINZESS: LINZESS® (linaclotide) Dosing | IBS-C, CIC & Functional constipation, captured 2026-11-14](https://www.linzesshcp.com/linzess-dosing#:~:text=Dosing%20adjustments%20for%20patients%20with%20renal%20or%20hepatic%20impairment%20are%20not%20required)

> “Renal or hepatic impairment is not expected to affect the clearance of linaclotide or the 
> active metabolite because linaclotide metabolism occurs within the gastrointestinal tract”

Source: [LINZESS: Prescribing information, page 13, captured 2026-11-14](https://www.rxabbvie.com/pdf/linzess_pi.pdf#page=13)

> “and plasma concentrations are not measurable in plasma following administration of the 
> recommended dosage.”

Source: [LINZESS: Prescribing information, page 14, captured 2026-11-14](https://www.rxabbvie.com/pdf/linzess_pi.pdf#page=14)

<a id="linzess-overdose"></a>

### What happens after a Linzess overdose?

> “Single LINZESS doses of 2897 mcg were administered to 22 healthy subjects; the safety 
> profile in these subjects was consistent with that in the overall LINZESS-treated population, 
> with diarrhea being the most commonly reported adverse reaction.”

Source: [LINZESS: Prescribing information, page 11, captured 2026-11-14](https://www.rxabbvie.com/pdf/linzess_pi.pdf#page=11)

## Related pages
- [Medical information: Linzess (linaclotide): All indications](https://www.evicenter.com/medical-information/linzess)
- [Indication](https://www.evicenter.com/medical-information/linzess/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/linzess/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/linzess/safety)
- [Drug interactions](https://www.evicenter.com/medical-information/linzess/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/linzess/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/linzess/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/linzess/access-and-coverage)
